Business
PainReform Provides Further Update on Manufacturing of PRF-110
TEL AVIV, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical
About this update from Prf Technologies Ltd.
[{"type":"text","content":"TEL AVIV, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (\"PainReform\" or the \"Company\"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a further update related to the manufacturing process of clinical batches for PRF-110. Ilan Hadar, Chief Executive Officer of Pain Reform, stated, “As previously announced, we implemented additional enhancements to our manufacturing process for PRF-110 expected to improve the efficiency and scalability of our manufacturing. We have since encountered issues in the manufacturing process, which will result in a delay in the commencement of our planned Phase 3 trial. We are moving aggressively on our plans and expect to report further updates as it relates to the expected start of the clinical study as soon as practical. Overall, we remain highly encouraged by the outlook for the business based on the success of our prior Phase 2 proof-of-concept clinical study. Assuming our Phase 3 trial is successful, we believe PRF-110 has the potential to become standard-of-care within the $12 billion post-operative pain treatment market and represents a highly attractive alternative to systemic opioids.” About PainReform PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The Company's proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. For more information, please visit www.painreform.com. Notice Regarding Forward-Looking Statements This press release contains forward looking statements about our expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as \"believe\", \"expect\", \"intend\", \"plan\", \"may\", \"should\", \"could\", \"might\", \"seek\", \"target\", \"will\", \"project\", \"...